0001567619-18-002676.txt : 20180914 0001567619-18-002676.hdr.sgml : 20180914 20180914181455 ACCESSION NUMBER: 0001567619-18-002676 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180912 FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Naarden Jacob CENTRAL INDEX KEY: 0001661254 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181072075 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-09-12 0 0001581720 Loxo Oncology, Inc. LOXO 0001661254 Van Naarden Jacob C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 0 1 0 0 Chief Business Officer Common Stock 2018-09-12 4 M 0 5500 3.648 A 19200 D Common Stock 2018-09-12 4 S 0 756 164.4383 D 18444 D Common Stock 2018-09-12 4 S 0 1885 165.3156 D 16559 D Common Stock 2018-09-12 4 S 0 1059 166.7380 D 15500 D Common Stock 2018-09-12 4 S 0 1000 167.3920 D 14500 D Common Stock 2018-09-12 4 S 0 200 168.785 D 14300 D Common Stock 2018-09-12 4 S 0 600 171.0267 D 13700 D Common Stock 2018-09-13 4 M 0 4500 3.648 A 18200 D Common Stock 2018-09-13 4 S 0 2700 165.4463 D 15500 D Common Stock 2018-09-13 4 S 0 1500 166.6347 D 14000 D Common Stock 2018-09-13 4 S 0 300 167.4867 D 13700 D Employee Stock Option (Right to Buy) 3.648 2018-09-12 4 M 0 5500 0 D 2024-06-18 Common Stock 5500 62769 D Employee Stock Option (Right to Buy) 3.648 2018-09-13 4 M 0 4500 0 D 2024-06-18 Common Stock 4500 58269 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.94 to $164.9399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.94 to $165.9399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.17 to $167.1699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.25 to $168.2499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.78 to $169.7799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.75 to $171.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.04 to $166.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.2599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.37 to $168.3699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/Jennifer Burstein, by power of attorney 2018-09-14